Israeli medtech outfit GI Dynamics, Inc. has launched its EndoBarrier® in its home market. The company has announced that The Sheba Medical Center (Tel Hashomer) at Ramat-Gan, Israel, is the first to offer the therapy, a non-surgical, non-pharmaceutical treatment for type 2 diabetes and/or obesity.
Let’s set the scene for EndoBarrier: According to the Israel Diabetes Association, there are an estimated 600,000 people in the country who are currently living with diabetes, and one-third of those are undiagnosed. According to the World Health Organization, overweight and obese people (BMI ≥25 kg/m2) have been estimated to account for about 65–80 percent of all new cases of type 2 diabetes.
EndoBarrier Therapy is an innovative, reversible medical device that enables patients to avoid the lifestyle changes and frequent post-surgical interventions associated with irreversible bypass surgery and gastric banding. This first-of-its-kind therapy is helping patients around the world fight their battle against type 2 diabetes and obesity while providing a pathway to a healthier lifestyle.
GI Dynamics received medical device registration approval for EndoBarrier from the Israeli Ministry of Health in February 2012 for the treatment of type 2 diabetes and obesity for up to 12 months. It is also currently available in Australia, Chile and select countries in Europe.
The company has entered into an agreement with Lavi – Medical Agencies (Lavi) as the exclusive distributor for EndoBarrier in Israel.
“Our diabetes center is at the forefront of innovative advances in managing type 2 diabetes and obesity, and we are pleased to offer EndoBarrier Therapy to our patients,” said Gabriella Lieberman, M.D., endocrinologist, head of obesity clinic, The Sheba Medical Center Institute of Endocrinology. “Our first groups of patients responded well to this brief, endoscopic procedure, and are achieving control of their diabetes while losing weight. It seems like EndoBarrier Therapy will become an integral part of our diabetes and obesity management program.”
“Our first patient cases in Israel mark yet another milestone in the global commercialization of EndoBarrier Therapy,” said Mark C. Twyman, chief commercial officer, GI Dynamics. “Sheba Center is a highly accredited, national institution that is renowned for delivering exceptional healthcare in Israel, and we are delighted to be working with them. In the coming months, we will continue to cultivate and train additional centers in Israel and work closely with our distributor to provide EndoBarrier Therapy to the many patients living with uncontrolled type 2 diabetes and obesity.”
Source: G I Dynamics, Inc.